Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
JNJ News
Johnson & Johnson JNJ delivered better-than-expected second quarter results, with the management hinting at leveraging tariff delays to maintain its outlook; ho...
Johnson & Johnson ( (JNJ) ) has released its Q2 earnings. Here is a breakdown of the information Johnson & Johnson presented to its investors. Elevate Your Inv...
J.P. Morgan analyst Chris Schott maintained a Hold rating on Johnson & Johnson yesterday and set a price target of $185.00. Elevate Your Investing Strategy: T...
Analyst ratings
60%
of 25 ratingsMore JNJ News
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Johnson & Johnson to $176 from $171 and keeps an Equal Weight rating on the shares. The f...
Johnson & Johnson recently reported second quarter 2025 results with sales of US$23.74 billion and net income of US$5.54 billion, alongside a raised full-year o...
In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Johnson & Johnson, with a price target of $185.00. Elevate Your Investing St...
After posting a double beat for Q2 2025, J&J (NYSE:JNJ), the pharma sector’s bellwether for the earnings season, added ~6% on Wednesday, marking its biggest int...
The drugmaker’s “grind it out” year is paying off, with sales jumping even as its blockbuster treatment faces more competition. Johnson & Johnson shares are th...
...
Johnson & Johnson JNJ on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68...
